Notable 52-Week Highs and Lows 10/19: (RF) (RTTR) (HAL) High; (CREE) (ACHC) (SGMO) Low

October 19, 2016 2:50 PM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

52-Week High:
  • Regions Financial (NYSE: RF) $10.61. Piper Jaffray reiterated an Overweight rating on Regions Financial and raised the price target from $11 to $11.50 following Q3 results Tuesday morning.

  • Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) $3.00. Ritter Pharma shares continuing higher from earlier in the week after announcing that the last patient has completed dosing and all monitoring visits in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance. Topline results of the trial are expected to be announced in the first quarter of 2017.

  • Halliburton (NYSE: HAL) $. Halliburton reported Q3 EPS of $0.01, versus the analyst estimate of ($0.07). Revenue for the quarter came in at $3.83 billion versus the consensus estimate of $3.9 billion.
52-Week Low:
  • Cree (Nasdaq: CREE) $21.50. Cree reported Q1 EPS of $0.09, versus the analyst estimate of $0.11. Revenue for the quarter came in at $321.3 million versus the consensus estimate of $322.77 million.

  • Acadia Healthcare Company, Inc. (Nasdaq: ACHC) $37.96. Acadia Healthcare announced the signing of a definitive agreement with BC Partners for the sale of 21 existing behavioral health facilities and one de novo behavioral health facility not yet opened, which are located in the United Kingdom. Acadia will receive £320 million (approximately $390 million) cash for the sale.

  • Sangamo Biosciences (Nasdaq: SGMO) $3.50. Sangamo Biosciences (Nasdaq: SGMO) disclosed the following in a U.S. SEC filing on Tuesday: On October 12, 2016, Geoffrey Nichol, M.B., Ch.B., notified Sangamo BioSciences, Inc. of his resignation as Executive Vice President, Research and Development effective October 25, 2016.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Related Entities

Piper Jaffray

Add Your Comment